Cleared Traditional

K130621 - BROADMASTER HEALTHCARE SYSTEM

K130621 is an FDA 510(k) clearance for BROADMASTER HEALTHCARE SYSTEM, manufactured by Broadmaster Biotech Corporation. The device is a Class 2 Chemistry device with product code NBW cleared through the Traditional 510(k) pathway after a 144-day FDA review.

K130621 · Broadmaster Biotech Corporation · Chemistry device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Jul 2013
Decision
144d
Days
Class 2
Risk

K130621 is an FDA 510(k) clearance for the BROADMASTER HEALTHCARE SYSTEM. Classified as System, Test, Blood Glucose, Over The Counter (product code NBW), Class II - Special Controls.

Submitted by Broadmaster Biotech Corporation (Zhonghe City, TW). The FDA issued a Cleared decision on July 30, 2013 after a review of 144 days - within the typical 510(k) review window.

This device falls under the Chemistry FDA review panel, regulated under 21 CFR 862.1345 - the FDA in vitro diagnostics and chemistry framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Standard predicate reliance. This clearance follows a standard predicate-based equivalence path within the Chemistry review framework, consistent with the majority of Class II 510(k) submissions.

View all Broadmaster Biotech Corporation devices

FDA 510(k) Submission Details - K130621

510(k) Number K130621 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received March 08, 2013
Decision Date July 30, 2013
Days to Decision 144 days
Submission Type Traditional
Review Panel Chemistry (CH)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
56d slower than avg
Panel avg: 88d · This submission: 144d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

NBW Device Classification - Class 2, Special Controls

Product Code NBW System, Test, Blood Glucose, Over The Counter
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 862.1345
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Chemistry devices follow this clearance model.

Regulatory Peers - NBW System, Test, Blood Glucose, Over The Counter

All 424
Devices cleared under the same product code (NBW) and FDA review panel - the closest regulatory comparables to K130621.
ACCU-CHEK AVIVA PLUS TEST STRIP
K131029 · Roche Diagnostics Operations, Inc. · Aug 2013
ACURA PLUS MULTI BLOOD GLUCOSE MONITORING SYSTEM
K131419 · I-Sens, Inc. · Aug 2013
GLUNEO BLOOD GLUCOSE MONITORING SYSTEM, AND PROFESSIONAL BLOOD GLUCOSE MONITORING SYSTEM
K130181 · Infopia Co, Ltd. · Jul 2013
LINKDR 2.0 DIABETES MANAGEMENT SOFTWARE
K130657 · All Medicus Co., Ltd. · Jul 2013
SOLUSMOBILE BLOOD GLUCOSE MANAGMENT SYSTEM
K123559 · Biotest Medical Corp. · Jun 2013
FREESTYLE PRECISION PRO BLOOD GLUCOSE AND B-KETONE MONITORING SYSTEM
K130094 · Abbott Diabetes Care · Jun 2013